Cargando…

Bone health in autosomal dominant polycystic kidney disease (ADPKD) patients after kidney transplantation

ADPKD is caused by pathogenic variants in PKD1 or PKD2, encoding polycystin-1 and -2 proteins. Polycystins are expressed in osteoblasts and chondrocytes in animal models, and loss of function is associated with low bone mineral density (BMD) and volume. However, it is unclear whether these variants...

Descripción completa

Detalles Bibliográficos
Autores principales: Zubidat, Dalia, Hanna, Christian, Randhawa, Amarjyot K., Smith, Byron H., Chedid, Maroun, Kaidbay, Daniel-Hasan N., Nardelli, Luca, Mkhaimer, Yaman G., Neal, Reem M., Madsen, Charles D., Senum, Sarah R., Gregory, Adriana V., Kline, Timothy L., Zoghby, Ziad M., Broski, Stephen M., Issa, Naim S., Harris, Peter C., Torres, Vicente E., Sfeir, Jad G., Chebib, Fouad T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842864/
https://www.ncbi.nlm.nih.gov/pubmed/36659900
http://dx.doi.org/10.1016/j.bonr.2023.101655
_version_ 1784870239083692032
author Zubidat, Dalia
Hanna, Christian
Randhawa, Amarjyot K.
Smith, Byron H.
Chedid, Maroun
Kaidbay, Daniel-Hasan N.
Nardelli, Luca
Mkhaimer, Yaman G.
Neal, Reem M.
Madsen, Charles D.
Senum, Sarah R.
Gregory, Adriana V.
Kline, Timothy L.
Zoghby, Ziad M.
Broski, Stephen M.
Issa, Naim S.
Harris, Peter C.
Torres, Vicente E.
Sfeir, Jad G.
Chebib, Fouad T.
author_facet Zubidat, Dalia
Hanna, Christian
Randhawa, Amarjyot K.
Smith, Byron H.
Chedid, Maroun
Kaidbay, Daniel-Hasan N.
Nardelli, Luca
Mkhaimer, Yaman G.
Neal, Reem M.
Madsen, Charles D.
Senum, Sarah R.
Gregory, Adriana V.
Kline, Timothy L.
Zoghby, Ziad M.
Broski, Stephen M.
Issa, Naim S.
Harris, Peter C.
Torres, Vicente E.
Sfeir, Jad G.
Chebib, Fouad T.
author_sort Zubidat, Dalia
collection PubMed
description ADPKD is caused by pathogenic variants in PKD1 or PKD2, encoding polycystin-1 and -2 proteins. Polycystins are expressed in osteoblasts and chondrocytes in animal models, and loss of function is associated with low bone mineral density (BMD) and volume. However, it is unclear whether these variants impact bone strength in ADPKD patients. Here, we examined BMD in ADPKD after kidney transplantation (KTx). This retrospective observational study retrieved data from adult patients who received a KTx over the past 15 years. Patients with available dual-energy X-ray absorptiometry (DXA) of the hip and/or lumbar spine (LS) post-transplant were included. ADPKD patients (n = 340) were matched 1:1 by age (±2 years) at KTx and sex with non-diabetic non-ADPKD patients (n = 340). Patients with ADPKD had slightly higher BMD and T-scores at the right total hip (TH) as compared to non-ADPKD patients [BMD: 0.951 vs. 0.897, p < 0.001; T-score: −0.62 vs. -0.99, p < 0.001] and at left TH [BMD: 0.960 vs. 0.893, p < 0.001; T-score: −0.60 vs. -1.08, p < 0.001], respectively. Similar results were found at the right femoral neck (FN) between ADPKD and non-ADPKD [BMD: 0.887 vs. 0.848, p = 0.001; T-score: −1.20 vs. -1.41, p = 0.01] and at left FN [BMD: 0.885 vs. 0.840, p < 0.001; T-score: −1.16 vs. -1.46, p = 0.001]. At the LS level, ADPKD had a similar BMD and lower T-score compared to non-ADPKD [BMD: 1.120 vs. 1.126, p = 0.93; T-score: −0.66 vs. -0.23, p = 0.008]. After adjusting for preemptive KTx, ADPKD patients continued to have higher BMD T-scores in TH and FN. Our findings indicate that BMD by DXA is higher in patients with ADPKD compared to non-ADPKD patients after transplantation in sites where cortical but not trabecular bone is predominant. The clinical benefit of the preserved cortical bone BMD in patients with ADPKD needs to be explored in future studies.
format Online
Article
Text
id pubmed-9842864
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-98428642023-01-18 Bone health in autosomal dominant polycystic kidney disease (ADPKD) patients after kidney transplantation Zubidat, Dalia Hanna, Christian Randhawa, Amarjyot K. Smith, Byron H. Chedid, Maroun Kaidbay, Daniel-Hasan N. Nardelli, Luca Mkhaimer, Yaman G. Neal, Reem M. Madsen, Charles D. Senum, Sarah R. Gregory, Adriana V. Kline, Timothy L. Zoghby, Ziad M. Broski, Stephen M. Issa, Naim S. Harris, Peter C. Torres, Vicente E. Sfeir, Jad G. Chebib, Fouad T. Bone Rep Full Length Article ADPKD is caused by pathogenic variants in PKD1 or PKD2, encoding polycystin-1 and -2 proteins. Polycystins are expressed in osteoblasts and chondrocytes in animal models, and loss of function is associated with low bone mineral density (BMD) and volume. However, it is unclear whether these variants impact bone strength in ADPKD patients. Here, we examined BMD in ADPKD after kidney transplantation (KTx). This retrospective observational study retrieved data from adult patients who received a KTx over the past 15 years. Patients with available dual-energy X-ray absorptiometry (DXA) of the hip and/or lumbar spine (LS) post-transplant were included. ADPKD patients (n = 340) were matched 1:1 by age (±2 years) at KTx and sex with non-diabetic non-ADPKD patients (n = 340). Patients with ADPKD had slightly higher BMD and T-scores at the right total hip (TH) as compared to non-ADPKD patients [BMD: 0.951 vs. 0.897, p < 0.001; T-score: −0.62 vs. -0.99, p < 0.001] and at left TH [BMD: 0.960 vs. 0.893, p < 0.001; T-score: −0.60 vs. -1.08, p < 0.001], respectively. Similar results were found at the right femoral neck (FN) between ADPKD and non-ADPKD [BMD: 0.887 vs. 0.848, p = 0.001; T-score: −1.20 vs. -1.41, p = 0.01] and at left FN [BMD: 0.885 vs. 0.840, p < 0.001; T-score: −1.16 vs. -1.46, p = 0.001]. At the LS level, ADPKD had a similar BMD and lower T-score compared to non-ADPKD [BMD: 1.120 vs. 1.126, p = 0.93; T-score: −0.66 vs. -0.23, p = 0.008]. After adjusting for preemptive KTx, ADPKD patients continued to have higher BMD T-scores in TH and FN. Our findings indicate that BMD by DXA is higher in patients with ADPKD compared to non-ADPKD patients after transplantation in sites where cortical but not trabecular bone is predominant. The clinical benefit of the preserved cortical bone BMD in patients with ADPKD needs to be explored in future studies. Elsevier 2023-01-11 /pmc/articles/PMC9842864/ /pubmed/36659900 http://dx.doi.org/10.1016/j.bonr.2023.101655 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Full Length Article
Zubidat, Dalia
Hanna, Christian
Randhawa, Amarjyot K.
Smith, Byron H.
Chedid, Maroun
Kaidbay, Daniel-Hasan N.
Nardelli, Luca
Mkhaimer, Yaman G.
Neal, Reem M.
Madsen, Charles D.
Senum, Sarah R.
Gregory, Adriana V.
Kline, Timothy L.
Zoghby, Ziad M.
Broski, Stephen M.
Issa, Naim S.
Harris, Peter C.
Torres, Vicente E.
Sfeir, Jad G.
Chebib, Fouad T.
Bone health in autosomal dominant polycystic kidney disease (ADPKD) patients after kidney transplantation
title Bone health in autosomal dominant polycystic kidney disease (ADPKD) patients after kidney transplantation
title_full Bone health in autosomal dominant polycystic kidney disease (ADPKD) patients after kidney transplantation
title_fullStr Bone health in autosomal dominant polycystic kidney disease (ADPKD) patients after kidney transplantation
title_full_unstemmed Bone health in autosomal dominant polycystic kidney disease (ADPKD) patients after kidney transplantation
title_short Bone health in autosomal dominant polycystic kidney disease (ADPKD) patients after kidney transplantation
title_sort bone health in autosomal dominant polycystic kidney disease (adpkd) patients after kidney transplantation
topic Full Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842864/
https://www.ncbi.nlm.nih.gov/pubmed/36659900
http://dx.doi.org/10.1016/j.bonr.2023.101655
work_keys_str_mv AT zubidatdalia bonehealthinautosomaldominantpolycystickidneydiseaseadpkdpatientsafterkidneytransplantation
AT hannachristian bonehealthinautosomaldominantpolycystickidneydiseaseadpkdpatientsafterkidneytransplantation
AT randhawaamarjyotk bonehealthinautosomaldominantpolycystickidneydiseaseadpkdpatientsafterkidneytransplantation
AT smithbyronh bonehealthinautosomaldominantpolycystickidneydiseaseadpkdpatientsafterkidneytransplantation
AT chedidmaroun bonehealthinautosomaldominantpolycystickidneydiseaseadpkdpatientsafterkidneytransplantation
AT kaidbaydanielhasann bonehealthinautosomaldominantpolycystickidneydiseaseadpkdpatientsafterkidneytransplantation
AT nardelliluca bonehealthinautosomaldominantpolycystickidneydiseaseadpkdpatientsafterkidneytransplantation
AT mkhaimeryamang bonehealthinautosomaldominantpolycystickidneydiseaseadpkdpatientsafterkidneytransplantation
AT nealreemm bonehealthinautosomaldominantpolycystickidneydiseaseadpkdpatientsafterkidneytransplantation
AT madsencharlesd bonehealthinautosomaldominantpolycystickidneydiseaseadpkdpatientsafterkidneytransplantation
AT senumsarahr bonehealthinautosomaldominantpolycystickidneydiseaseadpkdpatientsafterkidneytransplantation
AT gregoryadrianav bonehealthinautosomaldominantpolycystickidneydiseaseadpkdpatientsafterkidneytransplantation
AT klinetimothyl bonehealthinautosomaldominantpolycystickidneydiseaseadpkdpatientsafterkidneytransplantation
AT zoghbyziadm bonehealthinautosomaldominantpolycystickidneydiseaseadpkdpatientsafterkidneytransplantation
AT broskistephenm bonehealthinautosomaldominantpolycystickidneydiseaseadpkdpatientsafterkidneytransplantation
AT issanaims bonehealthinautosomaldominantpolycystickidneydiseaseadpkdpatientsafterkidneytransplantation
AT harrispeterc bonehealthinautosomaldominantpolycystickidneydiseaseadpkdpatientsafterkidneytransplantation
AT torresvicentee bonehealthinautosomaldominantpolycystickidneydiseaseadpkdpatientsafterkidneytransplantation
AT sfeirjadg bonehealthinautosomaldominantpolycystickidneydiseaseadpkdpatientsafterkidneytransplantation
AT chebibfouadt bonehealthinautosomaldominantpolycystickidneydiseaseadpkdpatientsafterkidneytransplantation